Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

39.72
Delayed Data
As of May 26
 -0.11 / -0.28%
Today’s Change
33.60
Today|||52-Week Range
50.40
+4.12%
Year-to-Date
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
May 25 / Zacks.com - Paid Partner Content
Mylan Stock Gains Following Barclays Upgrade
May 22 / TheStreet.com - Paid Partner Content
Starbucks' Howard Schultz Admits the Sight of Well-Known Activist Carl Icahn Causes H...
May 24 / TheStreet.com - Paid Partner Content
SuperGroup's wholesale change translates into sales
May 11 / FT.com - Paid Partner Content
Theravance/Mylan Presents Phase III Data on COPD Candidate
May 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close39.83
Today’s open39.75
Day’s range39.43 - 39.99
Volume3,974,189
Average volume (3 months)5,611,568
Market cap$21.3B
Dividend yield--
Data as of 4:14pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)+7.16%
Earnings growth (next 5 years)+7.03%
Revenue growth (last year)+17.44%
P/E ratio17.1
Price/Sales1.79
Price/Book1.92

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.67+0.77%
ALXNAlexion Pharmaceutic...-0.80-0.81%
INCYIncyte Corp-4.03-2.91%
VRTXVertex Pharmaceutica...+1.32+1.11%
Data as of 4:14pm ET, 05/26/2017

Financials

Next reporting dateAugust 10, 2017
EPS forecast (this quarter)$1.19
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts